Immunotherapy Use in Patients With Lung Cancer and Comorbidities

Area of Science:

• Oncology
• Immunology
• Clinical Medicine

Background:

• Immune checkpoint inhibitors (ICIs) are standard lung cancer treatment.
• Initial trials excluded patients with comorbidities like autoimmune diseases.
• Real-world data now informs ICI use in diverse patient populations.

Purpose of the Study:

• To evaluate the safety and efficacy of ICI therapy in lung cancer patients with comorbidities.
• To identify specific risks and considerations for ICI use in autoimmune disease populations.
• To guide clinical decision-making for ICI administration in complex patient cases.

Main Methods:

• Review of emerging real-world clinical experience and data.
• Analysis of safety profiles in patients with inactive low-risk autoimmune disease, renal/hepatic dysfunction, and chronic viral infections.
• Case-by-case evaluation framework for higher-risk autoimmune conditions and solid organ transplant recipients.

Main Results:

• ICIs can be safely administered to patients with inactive low-risk autoimmune disease (e.g., rheumatoid arthritis, psoriasis), mild-moderate renal/hepatic dysfunction, and certain chronic viral infections.
• Key considerations include potential autoimmune disease exacerbations, increased immune-related adverse events, and compromised efficacy with immunosuppression.
• Higher-risk autoimmune conditions and solid organ transplant recipients require careful, individualized assessment due to substantial risks.

Conclusions:

• Real-world evidence supports the safe use of ICIs in select comorbid lung cancer patients.
• Careful patient selection, risk stratification, and monitoring are essential for optimizing ICI therapy.
• Further research on predicting ICI efficacy and toxicity will enhance personalized treatment strategies.